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Abstract
In multiple myeloma, next-generation sequencing (NGS) has expanded our knowledge of genomic lesions, and highlighted a
dynamic and heterogeneous composition of the tumor. Here we used NGS to characterize the genomic landscape of 418
multiple myeloma cases at diagnosis and correlate this with prognosis and classiﬁcation. Translocations and copy number
abnormalities (CNAs) had a preponderant contribution over gene mutations in deﬁning the genotype and prognosis of each
case. Known and novel independent prognostic markers were identiﬁed in our cohort of proteasome inhibitor and
immunomodulatory drug-treated patients with long follow-up, including events with context-speciﬁc prognostic value, such
as deletions of the PRDM1 gene. Taking advantage of the comprehensive genomic annotation of each case, we used
innovative statistical approaches to identify potential novel myeloma subgroups. We observed clusters of patients stratiﬁed
based on the overall number of mutations and number/type of CNAs, with distinct effects on survival, suggesting that
extended genotype of multiple myeloma at diagnosis may lead to improved disease classiﬁcation and prognostication.
Key points
1. Next-generation sequencing allows analysis of
the integrated spectrum of gene mutations, aneuploidies
and IGH translocations in multiple myeloma.
2. Karyotypic events have a stronger impact on prognosis
than mutations, but extended genotyping shows novel
prognostic categories.
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Introduction
Multiple myeloma (MM) derives from the neoplastic
transformation and proliferation of a post-germinal center
B-cell. Karyotypic events are the main drivers of early
stages of transformation [1–3], and most MM cases are
either hyperdiploid (HDMM) or harbor translocations of
the immunoglobulin heavy chain (IGH) locus [4]. In
addition, several additional recurrent translocations and
copy number abnormalities (CNAs) can be found [5],
although at diagnosis, their analysis is usually limited to
events that have an established prognostic role and may
guide treatment: del17p, t(4;14) and t(14;16) [6, 7]. Gene
mutations are thought to be secondary events associated
with tumor progression rather than initiation [2, 8]. Several
next-generation sequencing (NGS) studies to date have
expanded our knowledge on the spectrum of gene muta-
tions in MM [8–13]. However, such studies have also
highlighted substantial heterogeneity and low recurrence
rates as compared to other hematological malignancies.
Furthermore, the integrated spectrum of gene mutations,
rearrangements and CNAs of each case is composed of
alterations that may belong to different subclones, often in
dynamic and differential evolution during the various
stages of disease [14]. NGS technologies are ideally suited
to return information on those driver events, whose ana-
lysis and correlation with clinical and laboratory features
of the patient can impact prognosis and disease classiﬁ-
cation. Initial efforts based on whole exome sequencing
(WES) have shown that integration of certain genomic
lesions into standard risk models can improve prog-
nostication in MM [13]. However, the full potential of
NGS studies has not been exploited so far. Custom target
pulldown (TPD) has signiﬁcant advantages over WES in
that it allows analysis of a limited fraction of the genome,
thus reducing the cost and complexity of downstream
analysis per sample. The success of this methodology
in detecting gene mutations at diagnosis or relapse has
been illustrated in myeloid malignancies [15–18] and MM
[19–21]. We have previously shown that TPD panels can
be designed to interrogate the integrated spectrum of gene
mutations, CNAs and IGH translocations in MM, thus
providing a potential one-stop platform for prognostication
of newly diagnosed MM cases [22]. Here we applied our
custom TPD to a large cohort of multiple myeloma sam-
ples at diagnosis to understand MM genomic and clinical
interrelationships. We report our unbiased analysis of a
large set of MM driver events, leading to the identiﬁcation
of novel prognostic factors and signiﬁcant interactions
between genomic events, and suggesting that analysis of
the extended myeloma genotype in larger cohorts
can identify novel subgroups that are biologically and
clinically distinct.
Methods
Sequencing and identiﬁcation of mutations
In total 10 ng of genomic DNA from CD138+ bone marrow
cells were subjected to whole-genome ampliﬁcation.
Patient-level tags were added and samples pooled before
custom target enrichment and sequencing, which was per-
formed on Illumina HiSeq2000 machines on a paired-end
75 bp protocol. Reads were aligned with BWA-mem and
variants called with in-house algorithms [23, 24] using a
previously described pipeline to ﬁlter out probable artifacts
and germline variants, and to rank somatic variants based on
their likely oncogenic potential [10, 15].
CNAs, IGH rearrangements and VAF adjustment
Coverage data were used to identify regions of aneu-
ploidies, after normalization to diploid samples. This was
performed at the whole-chromosome level, and from there
down to cytogenetic bands and gene loci. Hyperdiploid
samples were deﬁned by a gain in at least two of the
following chromosomes: 3, 5, 7, 9, 11, 15, 19, 21.
Translocations were called as previously described [22].
Gene-level CNA information was also used to adjust the
variant allelic frequency (VAF) of each variant, to estimate
the number of cells bearing a given variant, as previously
described [16].
Statistical analysis
Pairwise association studies were performed using Fisher
test corrected for multiple hypotheses testing. For survival
analysis, both progression-free (PFS) and overall survival
(OS) were used as end-points, and log-rank tests were used
for univariate hypothesis tests after correction for multiple
hypothesis testing. For multivariate survival analyses,
sparse Cox regression was performed on the full set of
driver events. Further information on methodology can be
found in the online supplement.
Results
Patients and sequencing metrics of the study
We used TPD to sequence unmatched genomic DNA from
373 MM patients at diagnosis, and we added 45 patients
from a previously published WES study [10] for a total of
418 (Table 1). Mean age was 56.6 years. Most patients
(76.3%) received bortezomib-based induction treatment
followed by autologous hemopoietic stem cell transplant.
First-line bortezomib-treated patients had a younger median
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age (55.6 vs 59.8 years, p= 1 × 10−5, Student's t-test).
Median follow-up was 5.4 years. At the time of analysis,
85.9% of patients relapsed, and 48.3% died.
We sequenced an average of 1.46 Gb per sample to a
target region depth of 118.9× (Supplementary Figure 1).
The average on-target efﬁciency was 34.3%, including the
IGH locus that shows extensive deletions in plasma cells,
leading to underestimation of the actual on-target efﬁciency
[22]. Although coverage was lower than our previous WES
study (Supplementary Figure 2A), the distribution of gene
mutations did not show any signiﬁcant differences (Sup-
plementary Figure 2B), suggesting that the overall perfor-
mance of our TPD was comparable to the previous WES
study.
Analysis of gene mutations in multiple myeloma
After excluding artifacts and likely germline single-
nucleotide polyorphisms, we identiﬁed 2269 high-con-
ﬁdence, likely somatic variants in 215 of the 246 genes
included in the design in 412 out of the 418 patients ana-
lyzed (Supplementary Table S1). We then compared the
expected pattern of mutations in each given gene derived
from the literature—typically inactivating mutations for
tumor suppressor genes and hot-spot mutations for onco-
genes—to the pattern observed in our series to triage each
variant into “oncogenic”, “possible oncogenic”, or
“unknown” classes (see Supplemental Methods for further
details). Looking at oncogenic mutations only, we found
695 variants in 106 genes in 342 patients (Fig. 1a). Num-
bers increased to 1250 variants in 177 genes in 395 patients
with the addition of possible oncogenic variants. At least
one oncogenic or possible oncogenic variant was found in
94.5% of patients, with a median of two per patient. The list
of most commonly mutated genes closely recapitulated
previously published data (Fig. 1b, top) [9–13]. Clustered
missense mutations were prevalent in known driver onco-
genes such as KRAS, NRAS and BRAF, whereas an excess
of truncating mutations was found in known tumor sup-
pressors such as TP53, FAM46C, SP140 (Fig. 1b, bottom).
Most oncogenic mutations (63%) were accounted for by
nine of the top driver genes previously identiﬁed, i.e.,
KRAS, NRAS, TP53, FAM46C, BRAF, DIS3, TRAF3,
SP140, IRF4 (Fig. 1b). A mutation in at least one of these
nine genes was found in 64% of patients. Conversely, many
genes showed a large excess of variants of unknown or
possible oncogenic potential. Among these, large genes like
FAT1, FAT3, FAT4, DNAH9, DNAH11, PCLO, whose role
in myeloma pathogenesis remains unclear [10, 13, 25]. Last,
we found sporadic oncogenic mutations with potential
clinical impact in CRBN and IKZF1, previously associated
with resistance to immunomodulatory drug [19, 26] in <1%
of patients each. Our mixed conﬁrmation/discovery effort
did therefore not identify novel genes mutated at a sig-
niﬁcant recurrence rate in MM, but at the same time we
showed how the long tail of uncommonly mutated genes
contributed a signiﬁcant fraction of the heterogeneous
genomic landscape of MM. Given the possible inclusion of
artifacts and/or germline variants in mutations of
“unknown” class, we only considered variants of oncogenic
or possible oncogenic classes as driver mutations for sub-
sequent analysis.
Table 1 Overall clinical features of cases included in the study
Variable Baseline
distribution
in cohort
Sample
Sample size for
sequencing
418
Sample size for
outcome data
418
Median (range)
follow-up
5.4
(0.1–11.5)
years
Demographics
Sex
Male 243 (58.1%)
Female 171 (40.9%)
NA 4 (1%)
Age, mean ±
SD
56.6 ± 8.4
years
Biochemical
β2
microglobulin,
mean ± SD
7.8 ± 9.6
(mg/L)
MM staging
ISS I 150 (35.9%)
ISS II 102 (24.4%)
ISS III 86 (20.6 %)
NA 80 (19.1%)
Treatment
VD-HDM 266 (63.6%)
VTD-HDM 53 (12.7%)
VAD-HDM 67 (16.0%)
MPV/KMP 5 (1.2%)
MPT 10 (2.4%)
RD 5 (1.2%)
SMM 1 (0.2%)
NA 11 (2.6%)
Outcome
Relapse 359/418
(85.9%)
Death 202/418
(48.3%)
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Overall, 56% of patients displayed activation of the
RAS/MAPK pathway, as clustered missense mutations of
KRAS, NRAS, BRAF, and truncating mutations of NF1 and
RASA2. The NF-kB pathway was recurrently hit as well,
with mutations—mostly inactivating—of TRAF3,CYLD
and LTB in 12% of patients. Last, mutations or deletions of
genes broadly implicated in the DNA damage response
(TP53, ATM, ATR, BRCA2) were observed in 22% of
patients. Although the mutational spectrum was hetero-
geneous and most genes showed low recurrence rates, fre-
quent involvement of these pathways conﬁrms their
functional relevance in MM pathogenesis.
Identiﬁcation of copy number changes and IGH
translocations allows analysis of the integrated
genomic landscape of myeloma
With most MM patients displaying prognostically relevant
structural abnormalities by karyotype or ﬂuorescence in situ
hybridization (FISH) analysis, we sought to derive this
information from our NGS data [22]. Recurrent IGH
translocations were identiﬁed in 135 out of 418 patients.
FISH validation for t(4;14) on 119 of them showed our
approach had 91% sensitivity and 98% speciﬁcity (Sup-
plementary Table S2). We identiﬁed 57% of patients as
HDMM and 32% as IGH-translocated (Fig. 2a). 9% of
patients harbored both an hyperdiploid karyotype and an
IGH translocation, and t(4:14) was the most prevalent in
this subgroup [27]. We then identiﬁed segmental chromo-
somal aneuploidies with prognostic signiﬁcance in 61% of
patients, at rates comparable to previous studies based on
SNP arrays [28]. Furthermore, we identiﬁed gene-level
gains and losses. Many gene ampliﬁcations were con-
cordant with whole-chromosome trisomies in hyperdiploid
cases, such as CCND1 in chromosome 11, prompting
exclusion of these events from further analysis. The most
frequent gene deletions instead consisted of known tumor
suppressors, and for TP53, CYLD, SNX7 these coexisted so
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Fig. 1 Absolute number of mutations in the study: a Left: absolute
numbers of genes with at least one mutation of the speciﬁed class
found in the study. Right: Number of patients carrying at least one
mutation of the speciﬁed class. Oncogenic variants: light blue. Possible
oncogenic variants: dark blue. Variants of unknown signiﬁcance:
orange. No variants identiﬁed: green. b Top: stacked bar chart of
mutations in the study, limited to genes with >2 oncogenic mutations,
broken down by mutation class. Bottom: For the same genes, missense
variants are in red, truncating variants are in gray
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frequently with larger segmental chromosomal deletions
that we aggregated loss of the gene locus and loss of the
chromosome segment as one variable for further analysis.
After these adjustments, genuine gene-level copy number
alterations were found in 51% of patients.
Considering recurrent translocations and aneuploidies,
deletions of tumor suppressor genes, ampliﬁcation of
oncogenes, and mutations pertaining to “oncogenic” or
“possible oncogenic” classes, at least one such driver event
was present in >99% of patients (Supplementary Fig-
ure 3A). Overall, a median of 6 events were present in each
patient (Fig. 2b). KRAS and NRAS were the only point
mutations present in the 15 most frequent driver events,
highlighting how karyotypic events dominate the integrated
genomic landscape of MM (Fig. 2c). In addition, we
interestingly found frequent deletions in genes required for
plasma cell development such as XBP1 and PRDM1
(Fig. 2c) that also show recurrent mutations, often truncat-
ing, suggesting they may represent novel tumor suppressors
in MM (Supplementary Table S1). Hyperdiploid cases
showed a small but signiﬁcantly higher average number of
mutations than cases with IGH translocations (2.75 vs 2.5,
chi-square test p= 0.002) (Supplementary Figure 3B),
suggesting that while additional genetic events are required
for disease progression, the evolutionary trajectory of each
myeloma case may vary based on the initiating event.
Predictive and prognostic value of individual
genomic events
We asked whether genomic features were correlated with
clinico-laboratoristic features. Using linear models, we
found only two associations. 17p deletions presented a
modest but signiﬁcant (p= 0.001, likelihood ratio test)
correlation with increasing age. Unlike myeloid disorders
[15, 16] and clonal hemopoiesis [29–33], here TP53
mutations were not correlated with age (Supplementary
Figure 4A, B), suggesting a different evolutionary trajec-
tory. Furthermore, 1q ampliﬁcation was signiﬁcantly cor-
related with higher beta-2 microglobulin levels (p= 0.003,
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Fig. 2 The genomic landscape of multiple myeloma: a Pie chart of the
breakdown of samples in the study, classiﬁed based on the presumed
founder cytogenetic abnormalities: hyperdiploidy and IGH transloca-
tions. HDMM hyperdiploid multiple myeloma, NA not available for
analysis, None no cytogenetic event identiﬁed. IGH_Tx translocation
involving the IGH region. b Bar chart of the prevalence of each class
of alteration (copy number abnormalities -CNA-, karyotype, gene-
level copy number abnormalities, gene mutations) in samples in the
study. c Stacked bar chart of the most frequent genomic events of any
class, broken down by cytogenetic group
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Supplementary Figure 4C). Among disease-independent
predictors of survival, older age was associated with poorer
survival as previously reported (Cox p= 0,019, Supple-
mentary Figure 4D) [34]. First line proteasome inhibitor
(PI) treatment was associated with improved PFS, and with
a trend towards improved overall survival (OS, Supple-
mentary Figure 4E), whose impact was more difﬁcult to
evaluate given the availability of PI-based salvage treatment
in the non-PI induction cohort. Finally, we found no sig-
niﬁcant association between genomic lesions and survival
for PI-treated patients, including no signiﬁcant beneﬁt from
bortezomib in t(4;14) [7]. The low frequency of most driver
events, and the likely modest size of the effect of a given
treatment on a driver event, warrant larger cohorts are
analyzed to answer this question in a comprehensive way.
We performed a univariate Cox analysis to infer the
prognostic value of each genomic feature for PFS and OS
(Supplementary Table S3). We found 12 variants sig-
niﬁcantly associated with poorer PFS and/or OS (Supple-
mentary Figure 5). Interestingly, most gene mutations were
not relevant for prognosis. The only mutated gene with a
clear prognostic impact on both PFS and OS was TP53,
while DNAH11 mutations conferred worse OS only (Log-
rank test, p= 6.9 × 10−4 and 7.3 × 10−3 for OS, respec-
tively). Looking at gene-level gains and losses, we found 5
events conferring shorter OS, including losses of TP53/17p,
CYLD/16q, FAT1, and ampliﬁcations of MYC and NRAS.
We could conﬁrm the negative impact on survival of t(4;14)
[4] and that of regions of recurrent CNAs [28] (that were
selected for their prognostic impact in the ﬁrst place).
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Fig. 3 Independent variants affecting survival: a Forest plot of vari-
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(right). Hazard ratio on the X axis, values <1 confer better prognosis,
values >1 confer worse prognosis. For each variable, the conﬁdence
interval is a horizontal gray bar and the hazard ratio—referenced to the
X-axis—is represented by a black box. b Kaplan–Meier survival
curves for two signiﬁcant instances of interaction found in the study:
prognosis for overall survival is signiﬁcantly worse in case of coex-
istence of PRDM1 deletions and t(4;14) (left) or PRDM1 deletions and
BIRC2/3 deletions (right) than with either variable alone
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Despite this selection bias, the lack of prognostic value of
most gene mutations and their overall lower level of
recurrence compared to cytogenetic changes underscores
the relevance of karyotypic events in shaping the clinical
behavior of MM.
Independent prognostic value of driver genomic
lesions and their interaction
We next performed a multivariate sparse Cox regression on
the full set of genomic variables. For PFS, 18 features had
non-zero coefﬁcients, with 9 of them being signiﬁcant in a
second multivariate Cox regression restricted to the ﬁrst
shortlist of 18 variables. Among these, mutations in
ATP13A4 and deletions in ARID4B had a favorable impact,
whereas mutations in SP140 and NRAS, t(4;14), amp(1q),
del(17p13) and deletions of FAT1 and PRDM1 had a
negative impact (Fig. 3a, left). For the OS regression, 13
features had non-zero coefﬁcients with 7 of them being
signiﬁcant in the restricted analysis: mutations in ATP13A4,
KDM6A and PRDM9 had a favorable impact, while t(4;14),
amp(1q), del(17p13), del(1p) had a negative impact
(Fig. 3a, right). Finally, because our cohort was hetero-
geneous in demographics and treatment received, we used
multivariate linear regression models to exclude a con-
founding effect of clinical features on the prognostic value
of each of these genomic variables, conﬁrming they can be
considered as independent prognostic events (Supplemen-
tary Figure 6).
Subsequently, we systematically looked for signiﬁcant
interactions between driver events, i.e. combinations where
the prognostic impact on OS of one is signiﬁcantly altered if
another is co-occurring. Despite the large set of variables,
we found only two signiﬁcant interactions: cases bearing
both t(4;14) and PRDM1 deletion had a dismal median OS
of 265 days (HR 9.05, p= 3 × 10−4 for interaction, Fig. 3b,
left); BIRC2/3 deletion and PRDM1 deletion conferred a
median OS of 666 days (HR 6.3, p= 0.04) (Fig. 3b, right).
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Fig. 4 Subclonal mutations:
a Stacked bar chart of the
clonality status of the top 11
mutated genes in our cohort:
bars refer to the left Y-axis and
plotted is the proportion of
variants that are subclonal
(orange), clonal (dark blue) and
presumed clonal (light blue)—
i.e., cases where conﬁdence
intervals of aVAF are all
overlapping and low tumor
purity could lead to over-
estimation of clonality. The
yellow line refers to the right Y-
axis and represents, for each
gene, the ratio between
subclonal and clonal variants,
i.e., higher values correspond to
genes with more subclonal
variants. (b)Kaplan–Meier plot
of progression-free survival in
patients with subclonal (red) or
clonal (blue) TP53 mutations
with p-values from univariate
analysis (log-rank test) adjusted
for multiple hypotheses testing.
c Kaplan–Meier plot of overall
survival in patients with
subclonal (red) or clonal (blue)
TP53 mutations with p-values
from univariate analysis (log-
rank test) adjusted for multiple
hypotheses testing
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When analyzed in isolation, PRDM1 deletions had no effect
(Supplementary Table S3), implying that the prognostic
value of driver oncogenic events in MM may differ based
on their genomic context.
We also looked for combinations of variables that could
be relevant for OS, even if not signiﬁcant for interaction,
across the whole dataset. We ﬁrst analyzed the association
of TP53 mutations and chr17p deletions, two events that are
known to co-occur [10], and the prognosis was slightly
worse for the combination (20/418 patients), in a trend
suggestive of an additive effect (Supplementary Figure 7A).
However, the shortest OS was that of t(4;14) and TP53
mutations (Supplementary Figure 7B), conferring a dismal
228 day median overall survival to patients bearing both
events. HDMM patients bearing an IGH translocation
showed a worse OS compared to those without (Supple-
mentary Figure 7C). On the same lines, OS was negatively
affected by the total number of driver oncogenic events,
irrespective of their nature, in a stepwise decline (Supple-
mentary Figure 7D), mainly supported by karyotypic events
(Supplementary Figures 7E-F). This reinforces the notion
that myeloma evolution toward more aggressive disease is
driven by acquisition of additional driver events.
Clonal and subclonal driver mutations
Adjusted VAF (aVAF) can be used to infer the fraction of
cells carrying each mutation, so to time its order of acqui-
sition [15, 16]. Subclonal mutations in known driver genes
such as KRAS, NRAS, TP53 were identiﬁed in 19.8%, 26%
and 26.7% of cases, respectively (examples in Supple-
mentary Figure 8A). When ranked based on the fraction of
subclonal occurrences, all genes had evidence of both clonal
and subclonal mutations, but CYLD and ZFHX4 had a
Fig. 5 Pairwise association between variables: Heatmap showing
pairwise analysis of occurrence of the most frequent genomic events in
MM. The same variable is plotted in the X and Y axis, and the intensity
of color in the leading diagonal indicated the frequency of the variable
in the dataset. In the upper triangle, intensity of green indicates the
frequency of co-occurrence of any two variables. In the lower triangle,
associations are colored by odds ratio: non-signiﬁcant ones are in gray,
while signiﬁcant ones are in blue if co-occurring, and red if mutually
exclusive (p-value < 0.05, ﬁsher test corrected for multiple hypothesis
testing). Events with false-discovery rate <0.1 are marked with a dot
and events with family-wise error rate <0.05 are marked with a star.
While only 47 variables are shown, statistical signiﬁcance is computed
on the full dataset of 192 variables shown in Supplementary Figure 10
Analysis of the genomic landscape of multiple myeloma… 2611
Fig. 6 Clustering of myeloma samples based on genomic landscape: a
Bayesian Dirichlet clustering process of the 418MM cases (in col-
umns) based on genomic variables (in rows, top panel), with verticals
black lines showing separation between identiﬁed clusters. A zoomed
in view for the karyotypic abnormalities is provided in the bottom
panel. Cluster 1 is composed of three patients where no driver event
could be identiﬁed. b For each of the four clusters, the histogram of the
distribution of gene mutations (top) and that of the CNAs (bottom) are
provided. c Progression-free (left) and overall survival (right)
Kaplan–Meier analysis of the four clusters
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somewhat higher percentage of subclonal variants, sug-
gesting these mutations may preferentially be acquired later
in myeloma evolution (Fig. 4a). TP53 was also more fre-
quently subclonal, but was nevertheless clonal in 11% of
myeloma cases. Conversely, IRF4 and DIS3 mutations were
most likely to be clonal and therefore acquired earlier in
evolution. We then looked at recurrent precedencies in
pairwise analysis of mutated genes, and again found no
recurrent pattern suggesting that mutations of driver genes,
in our sample size, do not follow preferential evolutionary
trajectories (Supplementary Table S4). Interestingly, we
found that multiple mutated alleles of driver gene mutations
-up to 5 for TP53- could be found at the subclonal level in a
signiﬁcant fraction of patients (Supplementary Figure 8B),
again highlighting the heterogeneous subclonal structure of
MM due to convergent evolution [35, 36].
The impact of clonal status on the prognostic value of gene
mutations is unclear for most cancers and has never been
studied in myeloma. Interestingly, we found that the clonality
status of mutations did not inﬂuence survival, with the
exception of a trend towards improved OS for TP53 subclonal
mutations (Fig. 4b, c, Supplementary Figure 9).
Patterns of co-occurring and mutually exclusive
events
Patterns of co-occurrence of driver events were system-
atically analyzed to look for potential cooperativity in
pairwise associations and functional redundancy for
mutually exclusive variables. In the list of 197 driver
events we identiﬁed 843 signiﬁcant interactions at p < 0.05
(Fisher Test), 15 at false-discovery rate <0.1 and 9 at
family-wise error rate <0.05 out of a total 19306 possible
interactions (Supplementary Figure 10, most frequent
events in Fig. 5). Among, signiﬁcant pairwise interactions,
some were previously described, such as the positive cor-
relation between chr13 and known poor prognostic factors
such as t(4;14), amp1q, del12p13.31, del17p13, TP53
mutations. KRAS and NRAS mutations were mutually
exclusive between each other but not with BRAF muta-
tions. We found a general pattern where mutations in tumor
suppressor genes co-occurred with deletion of the wild-
type allele in a typical double-hit manner for TP53, CYLD,
and TRAF3 mutations, supporting that these bi-allelic
events not only underlie relapse but may be present at
diagnosis as well [37]. Hyperdiploid and IGH-translocated
cases showed signiﬁcant differences in the spectrum of
associated genomic events. Chr13 deletions, chr1q ampli-
ﬁcations, DIS3 and ZFHX4 mutations were less frequent in
HDMM, which in turn was enriched for FAM46C muta-
tions. XBP1 deletions clustered with deletions of NF-kB
pathway genes TRAF3 and BIRC2/3, and with chromoso-
mal events such as chr12p, chr13, chr17p deletions and t
(4;14). Finally, t(11;14) and t(4;14) showed a diverse
spectrum of associated driver lesions, with t(4;14) cases in
particular being associated with chr13 deletions and chr1q
ampliﬁcations.
We then extended this analysis to uncover preferential
trajectories of cancer evolution highlighting different asso-
ciations of hotspot mutations within genes (Supplementary
Figure 11). We found a tendency for hotspot mutations in
KRAS, NRAS, BRAF, IRF4 to show a differential pattern of
co-occurrence, but none with a signiﬁcant false-discovery
rate.
Genomic structure suggests new myeloma subtypes
with clinical impact
The identiﬁcation of preferential patterns of associations or
mutual exclusivity of driver lesions, prompted us to explore
whether new myeloma subtypes could be identiﬁed based
on their extended genotype using a previously described
Bayesian model [16]. We could reliably identify four
clusters (Fig. 6a) of MM cases with good posterior prob-
ability of class assignment (Supplementary
Figure 12Ai–Aiii), albeit lower than acute myeloid leuke-
mia, which carry a simpler genomic structure [16]. Aside
from a small cluster 1 (3 patients) where no driver events
could be identiﬁed, most hyperdiploid and IGH-translocated
cases clustered together in the large cluster 3 (291 patients,
69.6%). We then identiﬁed two clusters, 2 and 4, composed
of 58 (13.9%) and 66 (15.8%) patients, respectively. Both
clusters were characterized by a signiﬁcantly lower number
of mutations but showed opposing features otherwise.
Cluster 2 was enriched for IGH translocations, had the
highest number of CNAs, was enriched for amp(1q), del
(13), del(17p), deletions of BIRC2/3 and XBP1 and carried
more TP53 mutations (Fig. 6b, Supplementary Figure 12B).
On the contrary, cluster 4 was mostly composed of hyper-
diploid cases and showed fewest CNAs and mutations
overall (Fig. 6b, Supplementary Figure 12B). There was no
association between treatment (PI, ASCT) and subgroups,
while cluster 4 was characterized by a slightly lower age
(Supplementary Figure 12C).
Prognosis was different for both PFS (Fig. 6c, left) and
OS (Fig. 6c, right) across the clusters. Cluster 2 showed the
worse median OS—1973 days—whereas cluster 4 was
associated with longer survival (median OS not reached),
again showing concordance between the number of CNAs
and prognosis.
Discussion
We provide the ﬁrst large-scale TPD effort in MM to
comprehensively describe its driver genomic landscape and
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how this impacts on clinical behavior. Compared to WES,
we reduced the amount of input DNA, the complexity of
downstream analysis and forwent the need for a matched
sample, to move this technology one step closer to the
clinic. Our approach was robust and conservative, and even
larger studies may allow re-classiﬁcation of events dis-
carded in our list as non-driver.
Gene mutations were frequent in our cohort; however,
we found a preponderant contribution of the few highly
recurrently mutated genes that were already described.
Nevertheless in individual cases, rare gene mutations may
impact treatment decisions. For example, CRBN, IKZF1 or
IKZF3 mutations (totaling a combined 1.6% of patients in
our cohort) would predict resistance to immunomodulatory
drug [26], whereas XBP1 deletions could predict bortezo-
mib resistance [38], suggesting future clinical-grade tar-
geted platforms must include rare driver events that have
predictive value for treatment.
Conﬁrming previous reports, the prognostic yield of
gene mutations was rather low in our large cohort as
compared to chromosomal events. PFS and OS were both
impacted only by TP53 mutations and by rare mutations
in ATP13A4, an ion transporter previously associated
with developmental disorders [39] but whose role in MM
was never reported before. We did not conﬁrm a prog-
nostic role of genes such as IRF4, EGR1 and ZFXH4 [13],
possibly because of front-line PI treatment and longer
follow-up of our cohort (63 months here vs 25 in ref.
[13]). We identiﬁed subclonal mutations for all recurrent
driver genes, showing that lesions classically associated
with disease progression can spontaneously arise before
diagnosis. As these lesions can be positively selected by
treatment, sensitive methods must be employed for their
identiﬁcation at diagnosis to achieve an accurate prog-
nostication. Some events had a strong, context-depen-
dent, prognostic value, such as deletions of PRDM1
coupled with either t(4;14) or BIRC2/3 deletions. These
interactions may be infrequent but are highly instructive
and clinically relevant, supporting the use of extended
gene panels in prognostic studies. However, to identify
more such instances, much larger sample sizes will be
needed given the heterogeneous genome of MM and the
expected modest effect of most interactions. In the future,
global risk calculators that incorporate extended clinical,
demographic, laboratoristic and genomic variables will
be able to address these points [40]. BIRC2/3 genes
deletions have been described in myeloma [41, 42],
whereas PRDM1 has only recently been identiﬁed as a
tumor suppressor based on recurrent truncating mutations
[11]. Truncations and deletions in PRDM1 were never-
theless previously described in lymphomas [43, 44],
where they are associated with poor prognosis [45].
Deletions of the 6q21 chromosome band containing the
PRDM1 locus are known to be recurrent in MM [46]. The
targeted nature of our study, however, did not allow us to
characterize the size of such deletions and thus we cannot
exclude that other tumor suppressors deleted in 6q con-
tributed to this observation.
Overall, driver events had an additive effect on
prognosis, showing that progressive accumulation of
abnormalities correlates with clinical aggressiveness,
almost independently of the nature of such events.
Therefore, our ﬁndings extend previous initial
observations on modulation of prognosis by additive
negative prognostic factors in FISH [47], and that
of aneuploidies in the prognosis of HDMM or IGH trans-
locations [48, 49].
Current MM classiﬁcation based on IGH translocations
or hyperdiploidy is reliable and biologically relevant, as it is
based on known early driver events. Here, we report on the
ﬁrst attempt toward a genomic classiﬁcation of myeloma
using innovative clustering algorithms based on the exten-
ded genotype of each patient. Allowing for the hetero-
geneity of the disease, we could identify disease subgroups
characterized by a different spectrum of translocations,
CNAs and gene mutations, as well as different contribution
by each class of events. A cluster of hyperdiploid cases
characterized by the fewest gene mutations and CNAs
showed a relatively good prognosis, whereas non-
hyperdiploid cases carrying multiple segmental chromoso-
mal aneuploidies and fewer gene mutations carried a worse
prognosis. Again, speciﬁc gene mutations did not contribute
much to the clustering. Similar to our analysis, a report
integrating MM expression proﬁles with mutational data to
identify subgroups with biological and prognostic values
showed little contribution of gene mutations to the clus-
tering [50]. However, knowledge of the mutational status of
a large number of genes allowed us to perform a prog-
nostically relevant clustering of cases based on the overall
mutational burden, supporting the value of analysis of
infrequently mutated genes. Lastly, a recent study also
reported on the dissection of hyperdiploid cases with dif-
ferent prognosis based on speciﬁc additional cytogenetic
lesions, supporting the validity of extended genotyping for
prognostication of MM [51].
The increasing availability of novel drugs and the
better understanding of pathways involved in MM pro-
gression prompts the need for rationalized treatment
approaches and mandates that high-risk disease is diag-
nosed with accuracy [52,53]. Probably, future genomic
studies will provide not only improved prognostication, but
also predictive factors of response and actionable mutations
that will help in treatment choices. The methodology and
results described here represent an important advance that
can accelerate the introduction of genomics in the clinical
approach to MM.
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